Nektar Therapeutics (NKTR) Financials

NKTR Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 763.3 million 187.1 million
Dec. 31, 2025 280.4 million 190.6 million
Sept. 30, 2025 301.3 million 216.3 million
June 30, 2025 207.5 million 231.7 million

NKTR Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -44.3 million ?
Dec. 31, 2025 -65.0 million 2.2 million
Sept. 30, 2025 -48.9 million 3.1 million
June 30, 2025 -45.8 million 3.5 million

NKTR Net Income

No data available :(

NKTR Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 568.6 million 60.3 million 60.6 million
Dec. 31, 2025 245.8 million 63.2 million 65.3 million
Sept. 30, 2025 270.2 million - 91.9 million
June 30, 2025 175.9 million - 96.2 million

NKTR Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 24.7 million
Dec. 31, 2025 20.3 million
Sept. 30, 2025 14.1 million
June 30, 2025 14.1 million

NKTR Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 18000 35.7 million 13.3 million -
Dec. 31, 2025 18000 29.7 million 11.4 million -
Sept. 30, 2025 114000 27.3 million 15.9 million -
June 30, 2025 37000 29.9 million 17.1 million -

NKTR Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 10.9 million 151000
Dec. 31, 2025 21.8 million -
Sept. 30, 2025 11.8 million 196000
June 30, 2025 11.2 million 214000

NKTR Revenue by Segment
Graph available only for paid members. Upgrade to see it.

NKTR

Price: $70.72

52 week price:
21.02
109.00

Payout Ratio Range:
-34.70%
-0.18%

Earnings Per Share: -7.93 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.8 million

Ebitda: 74.9 million

Market Capitalization: 1.4 billion

Links: